Longevity M&A & Dynamics
Sector and financial analysis; not medical advice.
Lifespan, healthspan: are we at an inflection point?
In France, life expectancy at birth has risen from about 39 years in 1830 to 83 today. Each step came from a discovery. The next one will target ageing itself.
- ACurrent trendPrevention, genomics, lifestyle · +2 years per decade
The curve keeps its momentum: prevention, screening, genomics and multi-omics, lifestyle optimisation, better treatment of chronic diseases. About two years gained per decade, as over the past fifty years.
- BLongevity medicineSenolytics, gene therapies, reprogramming · accelerating gains
Medicine no longer treats only diseases but ageing itself: senolytics that clear senescent cells, gene and cell therapies, partial epigenetic reprogramming, organ printing. Each decade then brings more than the one before.
- CLongevity escape velocityMore than one year gained per year · the most ambitious hypothesis
The point at which medicine would add more than one year of life expectancy per year elapsed. Coined in 2004 by Aubrey de Grey and David Gobel; Ray Kurzweil expects it in the 2030s, most researchers remain cautious.
Living longer is not enough: in France, healthy life expectancy plateaus at 70 years according to the WHO, twelve years short of lifespan.
Most of the longevity market focuses there first: extending those healthy years rather than waiting for age-related and chronic diseases to appear.
Source: WHO, Global Health Estimates 2021 – France: life expectancy at birth 81.9 years, healthy life expectancy (HALE) 70.1 years, i.e. 11.8 years lived in poor health. The curve above follows the INSEE series, hence the slight gap with the 83 years of 2026.
Sources: INED and INSEE, life expectancy at birth in France, both sexes, rounded values excluding war years; 2024: 82.9 years. Discovery dates: standard historical milestones; their position on the curve is indicative. Trajectories after 2026: illustrative scenarios, not forecasts.
For 4P, longevity covers every intervention that extends physical health and appearance: living longer in good health, and looking it. It combines lifestyle and care, from prevention to reprogramming therapies.
Why longevity is a booming market.
Ageing costs too much, younger generations turn it into a lifestyle, influencers make it mainstream and AI makes it credible: longevity is moving from science to market.
Sources: UN DESA, World Population Prospects 2022; INSEE, 2025 demographic report; OFDT (2026); IWSR (2025); Social Blade (Oct. 2026); McKinsey (May 2025); Google DeepMind (Nov. 2025).
Technological catalysts
GLP-1s make lifestyle mainstream. The first anti-ageing drug?
Semaglutide and tirzepatide: $66bn of sales in 2025, 12% of US adults treated. A revolutionary molecule, beyond weight: proven cardiovascular and renal effects, signals on inflammation and addiction. The whole fitness-maintenance wave rushes into this tsunami: muscle preservation, protein nutrition, exercise, supplements. Lifespan extension has so far only been shown in mice.
CRISPR-Cas9, reprogramming, gene therapies: ageing becomes a target.
CRISPR-Cas9 (Nobel 2020) had its first therapy approved in late 2023; in-vivo base editing draws big pharma (Verve acquired by Lilly in 2025); partial epigenetic reprogramming enters clinical trials; AI speeds up discovery (AlphaFold). The first therapies targeting ageing itself, rather than a disease, are reaching the clinic.
Sources: Novo Nordisk, Lilly (2025-2026); KFF (Nov. 2025); NEJM, SELECT trial (2023); FDA (Dec. 2023); Lilly / Verve (2025); Nature (2024-2026); Google DeepMind.
The economic case: prevention becomes profitable.
Sources: CNAM, Charges et produits 2026 and 2027 (2024 mapping: €210bn reimbursed, 65.1% for chronic diseases); DREES, Comptes de la santé 2025 and 2026 (2025 current health expenditure: €353.2bn); Deloitte, Breaking the cost curve (2021).
Three tiers, from lifestyle to cellular reset.
The higher you go, the heavier the science and the longer the horizon.
The first lever, and the cheapest. It is the foundation of the market: Gen Z turns health into a lifestyle, influencers make it mainstream. The total covers the eleven wellness sectors measured by GWI; the core of the tier comes down to three blocks: nutrition ($1,148bn, basic supplements included), exercise ($1,144bn: gyms, equipment, connected devices, competitions) and sleep ($107bn with sensory tech), the fastest-growing at +12.5% a year.
Functional nutrition: PepsiCo acquires poppi, a prebiotic soda brand, for $1.95bn (May 2025).
Sport: an L Catterton-led consortium takes a majority stake in Hyrox, the fitness racing series, valued at about €600m according to Bloomberg (September 2026).
The tier where deals happen today. It brings together everything that measures ageing and everything that slows it: connected devices, diagnostics, supplements, hormones, clinics, aesthetic and regenerative medicine. Three markets make up nearly three quarters of it: connected devices ($71bn), anti-ageing skincare ($56bn) and hormones (~$18bn). Strategic acquirers are already active: deal value here grew 16% a year between 2021 and 2025 and tripled in the first nine months of 2026.
Connected health devices: Oura, the smart ring tracking sleep and recovery, raises $900m at an $11bn valuation (October 2025).
Longevity clinics: AltamarCAM and King Street invest €95m in Lanserhof, preventive-medicine clinics and resorts (October 2025).
Gene and cell therapies ($9.7bn) and ageing drugs, senolytics, rapalogs, metformin and the TAME trial ($4.4bn): the science is in the clinic and no intervention has yet extended human life. Value rests on optionality and changes hands through licensing first, before buyouts: $10.4bn of deals since 2021, including $3.7bn in 2025, four times 2024.
Gene editing: Eli Lilly acquires Verve Therapeutics, in vivo gene editing against cholesterol, for $1.3bn, CVR included (June 2025).
Cellular reprogramming: NewLimit, which aims to rejuvenate cells through epigenetic reprogramming, raises $435m at a valuation of about $3.1bn (June 2026).
$66bn in 2025 sales, outside the three tiers: they are obesity and diabetes drugs, not ageing-well products.
Tier 1: GWI, Global Wellness Economy Monitor 2025 (2024 data: $6,763.6bn across the eleven wellness sectors, including nutrition 1,148, physical activity 1,144, sleep and senses 107; this total partly overlaps tier 2: beauty, fitness devices, personalised medicine). Tier 2: Grand View Research (2026: connected health devices, anti-ageing skincare outside medical channels, IV therapy), GMI (2025: energy-based aesthetic devices, all indications), Coherent Market Insights (2026: menopause treatment, $16.2bn) and GMI (testosterone, $1.9bn; hair loss treatments and supplements), TBRC (regenerative aesthetics; clinics), Mordor Intelligence (2026: physician-dispensed cosmeceuticals, $8.37bn, 37.3% anti-ageing, 4PLV calculation), NBJ, Credence, MarketsandMarkets, IMARC; diagnostics: 4PLV synthesis; base years 2024 to 2026, tier growth as an indicative weighted average. Tier 3: 4PLV synthesis. Deals (tier 2: peptides, diagnostics, clinics, injectables, consumer; tier 3: ageing biotech and cell therapies): cleaned 4PLV database, amounts paid on completed transactions, nine months = January to September. Compound annual growth rates computed point to point; deal value depends on a few large transactions and swings sharply from year to year.
Market Research Future: $32.15bn (Sept. 2026) · Mordor Intelligence: $29.77bn · SNS Insider: $27.61bn. Hair loss, regenerative aesthetics and tier 1 stay outside the consensus.
Market studies measure longevity in the strict sense; the real ecosystem is broader.
The regions: North America leads, Asia-Pacific grows fastest.
$31bn of “pure” longevity in 2025, $47-67bn expected by 2031-2035. Asia-Pacific combines the fastest growth (+10-11%/yr) with the technology edge: iPSC therapies in Japan, polynucleotides in Korea, ageing AI in China and Singapore, and a regulatory framework opening up in China (Decrees 818 and 828).
- United States: $9.2bn, +8.3%/yr; more than 120 longevity clinical trials; $3.7bn public ageing-research budget (NIA)
- Science and capital: Harvard (David Sinclair); Altos Labs $3bn, NewLimit $3.1bn, Retro $1.8bn; first human reprogramming trial (2026)
- Influence: Bryan Johnson, 2.8M followers, Blueprint $60m raised; “Outlive” (Peter Attia), 90 weeks a best-seller
- Congresses: A4M Las Vegas (since 1993), ARDD Boston, Abundance360 Los Angeles
- Spending: $2,140bn wellness economy, 32% of the world, $6,293 per capita (GWI); 7.4M aesthetic procedures (22%)
- Deals: close to 80% of the amounts invested in 2021-2026 go to North American targets
- Germany: 24% of the European market; United Kingdom: $2.0bn; $1,743bn wellness economy (+6.3%/yr, GWI)
- Spa and cure: 49% of global thermal-spa revenue (GWI); Lanserhof (~€100m revenue), Clinique La Prairie, SHA, Chenot, Buchinger
- Cosmetics: €104bn of sales (2024, world #2), €29bn exported, 38% of it by France; L’Oréal world #1
- Cradle of CMC-gel biostimulators: Radiesse (CaHA, Merz), Ellansé (PCL, Sinclair), Sculptra (PLLA, Galderma), Profhilo (IBSA)
- Medical aesthetics: 20% of the world market, 25% of hyaluronic acid; Galderma $5.21bn 2025 revenue (+17.7%)
- Switzerland: record density of premium clinics; scan-first: Neko (Sweden), Zoï (Paris, €20m)
- Japan: first conditional, time-limited approvals of iPSC therapies (Parkinson’s, heart failure, March 2026); 29% aged 65+
- Korea: leader in polynucleotides (PN/PDRN), exported worldwide
- China: 38% of the region; AI and biotech (Insilico, listed in Hong Kong)
- China: Decree 818 (in force 1 May 2026), a pathway separate from drug approval: after clinical research and authorisation, cell and gene-editing therapies may move into clinical application in qualified hospitals; Decree 828 (implementing regulations of the Drug Administration Law, 15 May 2026): up to 6 years of data protection, 7 years for rare diseases
- Singapore: AI applied to ageing (Gero)
- Regenerative medicine: +24%/yr in the region
- Saudi Arabia: 28% of the region; Hevolution, up to $1bn a year for ageing research
- Dubai: the Dubai Longevity Authority (Law No. 17, June 2026) targets close to $10bn of economic contribution in ten years
- Wellness: UAE +14.3%/yr, Saudi Arabia +12.2%/yr (GWI, 2019-2024), the fastest growth in the world
- UAE: cell-clinic licences; congresses Global Healthspan Summit (Riyadh) and Revive ME (Abu Dhabi)
- Longevity resorts: SHA Emirates (AlJurf, $163m, 120 suites), Clinique La Prairie Dubai; longevity residences (Six Senses, SHA, 2027)
- Brazil: world #2 in aesthetic procedures (3.1M, ISAPS 2024) and #1 in surgery; implants and fillers among the highest penetration rates
- Mexico: wellness +9.8%/yr (GWI); with Colombia, the highest share of foreign patients (ISAPS); SHA Mexico (2024)
- From aesthetics to longevity: “beauty from the inside out” (biostimulators, supplements, check-ups) converts the patient base
- Próspera (Honduras): its own regulatory framework; Minicircle (follistatin, ~$25,000, taken by Bryan Johnson), Unlimited Bio (Klotho, VEGF)
- Bahamas, Mexico, Panama: cell-therapy clinics a few hours from the United States, the laboratory of advanced therapies
Longevity market size in 2025 and expected annual growth. Sources: Market Research Future (Sept. 2026: $32.15bn in 2025, $66.40bn in 2035); Mordor Intelligence ($29.77bn); SNS Insider ($27.61bn); TBRC (2026); Global Wellness Institute (2024-2026); Longevity.Technology (2025-2026); The Medicine Maker, Morgan Lewis, ISAPS, Cosmetics Europe, Galderma, MIT Technology Review, Al Arabiya, Entrepreneur Middle East; China State Council (Decrees 818 and 828); 4PLV database and analysis. Rounded figures; Asia-Pacific and Middle East & Africa derived by difference.
Seven trends, products already identified.
Metabolism has become the centre of longevity, with GLP-1s as its main driver.
GLP-1s are moving to pills (oral Wegovy, orforglipron) and the price war begins. “Performance” peptides are leaving the grey zone: the FDA removed twelve peptides from its significant-risk list (April 2026), and its advisory committee voted in July for compounding BPC-157, TB-500 or MOTS-c (non-binding opinion: no authorisation at this stage).
Subscription blood panels, liquid biopsies, whole-body MRI, epigenetic clocks: testing becomes the gateway to longevity, and data platforms have raised at around 10 to 13 times revenue (Oura).
Medical resorts (Lanserhof, SHA, Clinique La Prairie), US memberships (Fountain Life), “hyperwellness” franchises (Restore Hyper Wellness, over 200 US centres), “scan-first” centres (Neko): value shifts from the stay to the subscription and real estate. By our estimates, multi-site platforms command clearly higher valuations than single centres.
Biostimulators, polynucleotides (PN/PDRN) and exosomes grow two to three times faster than classic hyaluronic acid, driven by post-GLP-1 demand; Korean and European leaders are the logical targets of the majors.
NAD+ precursors (NR, NMN), creatine, omega-3s, CoQ10, collagen peptides, anti-glycation actives: longevity supplements are the most liquid sub-categories. Subscription brands with clinical proof sell for around 3 times revenue (Nestlé, Kirin, L Catterton).
March 2026: Japan grants the first conditional approvals of iPSC therapies (Parkinson’s, heart failure). Secretome and exosomes point the way to cell-free regeneration, with no product yet approved in the United States.
First clinical trial of partial reprogramming (phase 1, 2026), NewLimit valued at $3.1bn, Big Pharma paying up to $1.3bn for in vivo editing, ageing drugs (senolytics such as dasatinib + quercetin, rapamycin and rapalogs, metformin with the TAME trial): breakthrough science enters the era of options and licences.
Sources: Novo Nordisk, Lilly (2025-2026); KFF (Nov. 2025); FDA (Apr. 2026); AJMC (Aug. 2026); Grand View Research; GMI; BCC Research; The Business Research Company (2026); The Medicine Maker (Mar. 2026); STAT (Jun. 2026); Galderma, PharmaResearch (2026); 4PLV analysis.
What acquirers pay.
2026: healthcare M&A is back in force.
After a weaker first half of 2025, buyers are back: healthcare M&A posts its best half-year since 2021 and more private equity funds are putting capital to work.
Sources: Mergermarket / ION Analytics (Jul. 2026); EY (PharmaVoice, Jul. 2026; BioXconomy, Sept. 2026); Bain & Company, Healthcare Private Equity 2026 Midyear Update (Aug. 2026); Longevity.Technology (Sept. 2026).
Longevity M&A.
Longevity biotech is following: $18.4bn raised or committed in 2025, a record, and already $12.1bn by 16 September 2026 (Longevity.Technology). Our proprietary base isolates these transactions across seven segments since 2021: here is what they say about prices.
Longevity · 7 segments
Multiples 2021-2026, disclosed or rebuilt from the target’s accounts; outliers excluded (EV/Sales above 50x, EV/EBITDA above 60x). Healthcare reference: 14.0x EBITDA and 3.5x revenue (PCE, Q2 2026). Exact Sciences / Abbott ($23bn, 2025), a borderline case, is excluded from totals. Indicative, not a valuation opinion. Sources: 4PLV database (19 October 2026), Capital IQ, company releases and financial press.
Transactions, acquirers and valuations: the full study.
Transactions, acquirers and valuations: we share the full study with founders, executives and investors in the sector.
Information from public sources and 4P Life Ventures analysis (October 2026). It constitutes neither investment advice nor a recommendation.